Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAT Therapy in Sepsis and Septic Shock
NCT04111822Phase 3Completed
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydrocortisone, ascorbic acid and thiamine in sepsis and septic shock (2 arms). Primary endpoints: Hospital survival after 28 days and Mortality at 7, 14 and 28 days. Started Oct 2018; status: completed.
02
Drugs
hydrocortisoneascorbic acidthiamine
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT04111822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111822.